SNOA
Sonoma Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$3.03
-0.03 (-0.98%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.77M | 1.82M | 1.63M |
| Net Income | 442.4K | 463.1K | 348.9K |
| EPS | — | — | — |
| Profit Margin | 24.9% | 25.4% | 21.5% |
| Rev Growth | +8.7% | -7.1% | +16.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 924.2K | 821.0K | 810.3K |
| Total Equity | 2.90M | 2.76M | 3.02M |
| D/E Ratio | 0.32 | 0.30 | 0.27 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 588.1K | 609.2K | 511.6K |
| Free Cash Flow | 272.5K | 381.4K | 338.4K |